Trimunocor is a dynamic spin-out formed to leverage innovations from the Medical Research Council and the University of Southampton focused on finding solutions to combat neonatal chronic lung disease. Our primary innovation centres around the development of natural anti-inflammatory and anti-microbial protein surfactant, protein D for a broad range of anti-inflammatory lung diseases.
To deliver this innovation our team brings together world leading scientific talent, expansive clinical networks and renowned commercial experience together into a team that is poised to deliver exceptional results.
Dr Neill Mackenzie is an internationally networked pharmaceutical executive and serial entrepreneur. Over the last 16 years, Neill has served on the Boards of Trimunocor, Cellualr Therapeutics Ltd, Biotecnol Ltd, CMP Therapeutics Ltd, Roji Ltd Medigene AG, Avidex Ltd, Oxford BioMedica plc, BioMedica Inc and Cambridge Genetics Ltd. As an Executive Director with P&L responsibilities, in listed (both London Stock Exchange and AIM) and private companies he has raised over $150 million equity capital from private and public funds.
Prof Howard Clark BA MA MB BChir MA MD (Cantab) MA DPhil (Oxon) MRCP FRCPCH is Professor of Neonatal Medicine and Child Health, Honorary Consultant in Neonatal Medicine, UCLH, and Deputy Director UCL EGA Institute for Women's Health, Faculty of Population Health Sciences. He leads the surfactant biology group at UCL which aims to develop recombinant surfactant proteins A and D as novel therapy for lung inflammation. Prof Clark has over 50 publications on neonatal medicine and surfactant and is the previous President Elect of The Neonatal Society, the foremost internationally recognised neonatal research society. Prof Clark is Co-Founder, with Dr Neill Mackenzie of Trimunocor.
Dr. Alastair Watson gained his PhD in innate lung immunology (University of Southampton) and published numerous papers related to innate lung immunology. He developed a new recombinant immunity protein (recombinant surfactant protein A) efficient at preventing respiratory virus infection. Alastair also developed novel expression systems to allow for pharmateutical development of recombinant surfactant protein D. After training on the ICURe programme and being awarded an Aid for Start-up Innovate grant, Alastair is now project managing the commercialisation of rfhSP-D into a therapeutic for inflammatory lung diseases.